Radiation Therapy
IMRT for Brain Cancer
"This trial is comparing a newer type of radiation therapy called intensity modulated radiation therapy (IMRT) to the standard whole brain radiation therapy for treating brain metastases. The study aims to see if IM
Monoclonal Antibodies
Trastuzumab Emtansine Safety for Cancer
This trial is for people who have been receiving treatment with either trastuzumab emtansine or a combination of it with other anti-cancer therapies, and who are still benefiting from the treatment. The purpose of the trial is to continue to monitor the safety of the treatment.
Monoclonal Antibodies
Pembrolizumab Combinations for Cancer
"This trial will test a drug called pembrolizumab in combination with other drugs in children with certain types of cancer. The study will have two parts: the first part will focus on safety and
Kinase Inhibitor
LOXO-435 for Bladder Cancer
This trial is testing LOXO-435, a new drug, to see if it can help treat advanced cancers with a specific genetic change. It aims to block a gene that helps cancer cells grow. The study will check the drug's safety and effectiveness in these patients. LOX may be a potential effective therapeutic target to treat colorectal cancer.
Popular Filters
Trials for Cancer Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Chemotherapy
EMB-01 for Advanced Cancer
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
PD-1 Inhibitor
Immunotherapy for Advanced Cancer
This trial is testing a new immunotherapy in adults with advanced cancer. The goal is to see if it helps the immune system fight cancer, and if it's well-tolerated. Participants will be in the study for varying lengths of time, depending on how well they respond to treatment and if they experience any side effects.
Trials for Solid Tumors Patients
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Chemotherapy
EMB-01 for Advanced Cancer
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
PD-1 Inhibitor
Immunotherapy for Advanced Cancer
This trial is testing a new immunotherapy in adults with advanced cancer. The goal is to see if it helps the immune system fight cancer, and if it's well-tolerated. Participants will be in the study for varying lengths of time, depending on how well they respond to treatment and if they experience any side effects.
Phase 3 Trials
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Monoclonal Antibodies
LY3537982 + Immunotherapy/Chemotherapy for Non-Small Cell Lung Cancer
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Opioid Analgesic
Pain Medication for Postoperative Pain
This trial is testing whether adding Toradol, an anti-inflammatory drug, to the usual opioid painkillers can better manage pain after surgery in patients who have had a specific type of bone surgery. These patients are chosen because they don't need the body's natural inflammation process for healing. Toradol works by reducing inflammation, while opioids change how the brain perceives pain. Toradol, also known as ketorolac, is a nonsteroidal anti-inflammatory drug (NSAID) that has been studied for its opioid-sparing effects in postoperative pain management.
Trials With No Placebo
Selective Estrogen Receptor Downregulator (SERD)
Imlunestrant + Abemaciclib for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Small Molecule Inhibitor
BI 1810631 for Advanced Cancer
This trial is testing a new medicine called BI 1810631, which is taken as tablets. It targets adults with advanced cancers that have specific genetic changes and have not responded to other treatments. The goal is to find a safe dose and see if it can help shrink tumors.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Chemotherapy
EMB-01 for Advanced Cancer
This trial is testing a new medicine called EMB-01 in patients with advanced cancers who have no other treatment options. EMB-01 aims to block two proteins that help cancer cells grow, making it harder for the cancer to survive.
PD-1 Inhibitor
Immunotherapy for Advanced Cancer
This trial is testing a new immunotherapy in adults with advanced cancer. The goal is to see if it helps the immune system fight cancer, and if it's well-tolerated. Participants will be in the study for varying lengths of time, depending on how well they respond to treatment and if they experience any side effects.
View More Related Trials
Frequently Asked Questions
Introduction to bone metastases
What are the top hospitals conducting bone metastases research?
When it comes to advancing treatment options for patients with bone metastases, several hospitals are leading the charge. In Houston, M D Anderson Cancer Center takes center stage with an impressive 16 active trials focused on this condition and a total of 23 completed trials since their first recorded study in 2004. Not far behind is Memorial Sloan Kettering Cancer Center in New york, where eight ongoing bone metastases trials contribute to a remarkable tally of 64 all-time completed studies since their pioneering trial in 2003.
Meanwhile, at Dana-Farber Cancer Institute in Boston, researchers are currently conducting seven active clinical trials targeting bone metastases while having achieved significant milestones through their involvement in 34 previous investigations dating back to as early as1999. Further west, Washington University School of Medicine based in Saint Louis dedicates itself to combatting this condition with six ongoing clinical trials and a respectable history encompassing fifteen previously conducted studies since initiating their inaugural trial dedicated solely toward understanding bone metastases backin2008.
Additionally adding itself to this list is The University of Texas MD Anderson Cancer Center located within Houston; they presently participate actively within four comparable research initiatives concerning treating such cases directly contributing towards twelve additional experiments regarding concurrent circumstances originating from just ten years ago until2011.
These esteemed medical institutions serve as beacons of hope for those living with bone metastases and exemplify the tireless efforts being made nationwide to enhance patient outcomes. By pushing the boundaries of scientific knowledge through these groundbreaking clinical trials, they bring us one step closer to more effective treatments that can alleviate suffering and improve quality of life for individuals battling this challenging condition.
Which are the best cities for bone metastases clinical trials?
When it comes to bone metastases clinical trials, several cities have emerged as leaders in research and development. Houston, Texas leads the pack with 35 active trials. New york, New York follows closely behind with 23 ongoing studies, while Boston, Massachusetts and Los Angeles, California both have 22 and 17 active trials respectively. Atlanta, Georgia also joins the list with 17 active trials dedicated to exploring various treatment options. These cities offer individuals affected by bone metastases access to groundbreaking clinical trials that pave the way for advancements in care and provide hope for improved outcomes.
Which are the top treatments for bone metastases being explored in clinical trials?
In the realm of bone metastases, clinical trials are exploring a range of potential treatments that hold promise for patients. Leading the charge is stereotactic radiosurgery, currently being tested in seven active trials and boasting 21 all-time trials dedicated to bone metastases since its introduction in 2004. Another contender gaining traction is abemaciclib, with three ongoing trials and an impressive track record of 12 all-time studies focused on this condition since 2014. Additionally, EMB-01 is showing potential with two active trials and two all-time bone metastases trials since its listing in 2018. Lastly, pembrolizumab demonstrates promise too as it participates in two ongoing clinical trials while accumulating substantial experience with a total of 29 all-time bone metastases studies since first listed in 2015. These endeavors bring hope for improved treatment options to those affected by bone metastases worldwide
What are the most recent clinical trials for bone metastases?
Recent clinical trials offer hope for patients dealing with bone metastases, a challenging condition that arises when cancer spreads to the bones. One such trial focuses on the potential benefits of cemiplimab treatment specifically tailored for bone metastases. Another study investigates the combined approach of stereotactic body radiation therapy (SBRT) and androgen deprivation therapy (ADT), aiming to establish a new standard of care for this condition. Additionally, there is ongoing research into diagnostic techniques like 89Zr panitumumab PET/CT, which can aid in accurately identifying and assessing bone metastases. These innovative approaches demonstrate the dedication of researchers towards finding effective solutions for individuals affected by bone metastases.
What bone metastases clinical trials were recently completed?
Recent clinical trials have made significant progress in the field of bone metastases, aiming to improve treatment options for patients. One such trial, sponsored by the University of Utah and completed in June 2022, focused on MRI Brain and Cervical Spine. Mirati Therapeutics Inc.'s MRTX849 trial was also successfully concluded in August 2021. Additionally, I-Mab Biopharma Co. Ltd.'s TJ210001 trial reached completion in December 2020. These trials highlight the commitment of researchers to advance our understanding and management of bone metastases, offering hope for patients dealing with this challenging condition